Study of Quality of Life and Hormone Levels in Premenopausal Participants With Early Breast Cancer Receiving Triptorelin Plus Additional Cancer Treatment
← catalyst calendarSponsored by Ipsen (industry) · IPN.PA — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
450actual
Sites
22
Country
Italy
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-06-09 | actual | When the study began enrolling |
| Primary completion | 2026-06-04 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-04 | actual | The whole study's end, after follow-up |
| First posted | 2022-05-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Early-stage Breast Cancer
Primary outcome
what the primary-completion date above is the date OFProportion of participants reaching a clinically significant change in the global Quality of Life (QoL) score.
measured At 18 months.
Permalink · IPN.PA's whole pipeline · Catalyst calendar · Every registered study · What changed